Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
On September 28-29, 2022, PhRMA hosted the second annual Pathways to Success: Virtual Graduate Summit and Career Expo. This event provided a unique opportunity for students and faculty from diverse backgrounds to engage with biopharma recruiters and employees. For the second year in a row, our attendees discovered career opportunities and built connections in the biopharma industry, all while learning valuable knowledge from mentors and thought leaders. (Source: The Catalyst)
Source: The Catalyst - December 8, 2022 Category: Pharmaceuticals Authors: Dr. Steven Thomas Tags: PhRMA Member Company Equity Source Type: news
In their own words: Financial barriers exacerbate access challenges for insured Americans
A survey of more than 5,000 Americans conducted with Ipsos found that 30% of insured Americans say they face a financial barrier to care, such as unaffordable out-of-pocket costs or a lack of savings to pay for emergency or unforeseen expenses. (Source: The Catalyst)
Source: The Catalyst - December 8, 2022 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Health Insurance Out-of-Pocket Costs Pharmacy Benefit Managers Polling Source Type: news
Traditional HTAs keep diverse patients out of the conversation
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments. Inthis series, we explore some of the key short-comings of traditional HTA, particularly how it: (Source: The Catalyst)
Source: The Catalyst - December 7, 2022 Category: Pharmaceuticals Authors: Katie Koziara Tags: Value Assessment Health Equity Source Type: news
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports abroad range of STEM jobs through R&D and manufacturing. At the backbone of the biopharmaceutical ecosystem are its researchers. Each day, in labs across the country, these individuals work tirelessly on the front lines of research and development to help bring novel medicines to patients. This challenge is far from easy. More often than not, the process of researching and developing innovative treatments is fraught with more setbacks than successes. Despite this, hearing first-hand testimonies from rese...
Source: The Catalyst - December 1, 2022 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Medicines in Development Research and Development PhRMA Member Company Cancer Source Type: news
What they are saying: PASTEUR Act can help fight antimicrobial resistance
Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and1.27 million globally on an annual basis – higher than HIV/AIDS and malaria. To slow and control continued AMR, we need a robust pipeline of novel products, and at the same time we need to ensure they are used only in a limited set of circumstances and in only the most necessary cases. Without new products to address the problem, AMR glo bally could take 10 million lives yearly by 2050. Countless modern medical advances that depend on antibiotics—such as routine surgery, cancer therapy and treatment of chronic ...
Source: The Catalyst - November 30, 2022 Category: Pharmaceuticals Tags: Antimicrobial Resistance Source Type: news
Word of the Month: What is TRIPS?
What is TRIPS? (Source: The Catalyst)
Source: The Catalyst - November 29, 2022 Category: Pharmaceuticals Authors: Ernest Kawka and Douglas Petersen Tags: Vaccines Coronavirus TRIPS Waiver Word of the Month Source Type: news
Putting Delaware patients first: Protecting Patient Assistance Programs
Patients with chronic health conditions in Delaware are seeing a new wave of relief thanks to Governor John Carney, members of the Delaware legislature and more than 40 patient groups. The recently passedSB267 will make it easier for vulnerable patients to be able to afford their brand medications. (Source: The Catalyst)
Source: The Catalyst - November 22, 2022 Category: Pharmaceuticals Authors: Stami Williams Tags: Patient Assistance Programs Out-of-Pocket Costs Source Type: news
How HTA-based price controls could worsen health outcomes and health disparities
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments. In thisseries, we ’ll explore how this controversial practice: (Source: The Catalyst)
Source: The Catalyst - November 22, 2022 Category: Pharmaceuticals Authors: Katie Koziara Tags: Value Assessment Equity Source Type: news
The 340B program is interfering with the U.S. biosimilars market and impacting patient costs
Research has shown that 340B hospitals are more likely toprescribe more expensive medicines andsignificantly mark up the price of medicines. For example, 340B hospitals received nearly five times what they paid, on average, to acquire oncology medicines through 340B. These practices have implications for what patients pay out of pocket — and new research adds to the evidence. Anew Milliman analysis found340B hospitals have lower utilization of biosimilars than non-340B hospitals among their commercially insured patients, potentially leading to higher out-of-pocket costs for some patients. (Source: The Catalyst)
Source: The Catalyst - November 21, 2022 Category: Pharmaceuticals Tags: 340B Biologics and Biosimilars Source Type: news
Medicare Part D open enrollment and what recent changes mean for beneficiaries
It ’s that time of year again:Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their Part D prescription drug plans for 2023 through Wednesday, December 7. Part D beneficiaries have a variety of plans to choose from, ranging from 24 to 32 options in each state. As a result of Part D, nearly 90% of Medicare beneficiaries have comprehensive drug coverage, amounting to more than47 million beneficiaries in 2020. But open enrollment can be confusing. (Source: The Catalyst)
Source: The Catalyst - November 17, 2022 Category: Pharmaceuticals Tags: Health Insurance Part D Medicare Source Type: news
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development
The United States has led the charge in thedevelopment of vaccines and treatments to combat COVID-19 thanks in large part to our robust innovation ecosystem, supported by intellectual property (IP) protections. The decision made by the Biden Administration and other WTO members earlier this year to waive commitments to protect IP on COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement washarmful and unnecessary and removed the very incentives that enable scientific advancement. Expanding the TRIPS waiver to include COVID-19 treatments — as some WTO members wish to do — wou...
Source: The Catalyst - November 17, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Research and Development Intellectual Property TRIPS Waiver Source Type: news
Six ways I-MAK is lying about biopharma patents
TheArnold-Venture funded advocacy group Initiative for Medicines, Access& Knowledge, Inc. (or I-MAK) is on a global media tour, espousing their point of view on the patent system. Someexperts and congressional leaders don ’t buy the rhetoric, and neither should you. Here are the top myths to look out for: (Source: The Catalyst)
Source: The Catalyst - November 16, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Patents Intellectual Property Source Type: news
New data show how insurers and middlemen shift Rx costs onto patients
There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that ’s at the pharmacy counter. Anew report reveals how this harmful tactic leads to higher costs for patients. (Source: The Catalyst)
Source: The Catalyst - November 16, 2022 Category: Pharmaceuticals Authors: Brian Newell Tags: Adherence Drug Cost Health Insurance Out-of-Pocket Costs Pharmacy Benefit Managers Source Type: news
What you should know about RSV
You are probably reading a lot about a surge of cases of respiratory viruses like respiratory syncytial virus (RSV), influenza (the flu) and SARS-CoV-2, which causes COVID-19. The triple threat of these highly contagious respiratory viruses circulating simultaneously is causing a ripple of effects on patients, health care providers and our health care system as a whole. (Source: The Catalyst)
Source: The Catalyst - November 15, 2022 Category: Pharmaceuticals Authors: Mike Ybarra Tags: Vaccines Infectious Diseases Source Type: news
TRIPS waiver expansion risks public health
The Biden administration and other World Trade Organization members are considering expanding the harmful and unnecessary waiver of intellectual property (IP) protections under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) beyond COVID-19 vaccines. These governments should approach this decision with a clear understanding of one of the most significant consequences of that action: compromised public health, especially in lower-income countries. (Source: The Catalyst)
Source: The Catalyst - November 14, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Coronavirus TRIPS Waiver Source Type: news
